Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. | J Immunol;179(4): 2493-500, 2007 Aug 15. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.

Li, Jiali; Song, Wenru; Czerwinski, Debra K; Varghese, Bindu; Uematsu, Satoshi; Akira, Shizuo; Krieg, Arthur M; Levy, Ronald.

Affiliation

Li J; Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA 94305, USA.

J Immunol ; 179(4): 2493-500, 2007 Aug 15.

Article in En | MEDLINE | ID: mdl-17675511

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Oligodeoxyribonucleotides / Adjuvants, Immunologic / Lymphoma, B-Cell / Antigen Presentation / Toll-Like Receptor 9 / Neoplasm Proteins Limits: Animals / Humans Language: En Journal: J Immunol Year: 2007 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Oligodeoxyribonucleotides / Adjuvants, Immunologic / Lymphoma, B-Cell / Antigen Presentation / Toll-Like Receptor 9 / Neoplasm Proteins Limits: Animals / Humans Language: En Journal: J Immunol Year: 2007 Document type: Article Affiliation country: Country of publication: